Pharmaceutical Technology13 天
Tevimbra by BeiGene for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase II for Primary Mediastinal B-Cell Lymphoma.
Pharmaceutical Technology13 天
Calquence by AstraZeneca for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Calquence is under clinical development by AstraZeneca and currently in Phase II for Primary Mediastinal B-Cell Lymphoma.
Oncology Nurse Advisor9 天
Some Patients With PMBCL May Safely Forego Irradiation During Consolidation
Researchers sought to determine whether patients with PMBCL may be able to forgo irradiation therapy during consolidation.